Overview
Founded in 2020 in Nivelles, Wallonia, Quantoom Biosciences is developing technology for the large-scale, cost-efficient production of mRNA and lipid nanoparticle (LNP) formulation for pharmaceutical applications. The company's platform addresses manufacturing bottlenecks that constrained mRNA medicine scale-up during and after the COVID-19 pandemic.
Quantoom targets the growing pipeline of mRNA-based medicines beyond vaccines, including oncology, rare diseases, and protein replacement therapies. As the mRNA field expands beyond emergency use, efficient and GMP-compliant manufacturing infrastructure becomes critical. The Nivelles location in Wallonia connects the company to the region's biotech cluster, which includes Univercells and Ziphius Vaccines.
Key people
In the news
- The 27th Developing Countries Vaccine Manufacturers Network (DCVMN International) Annual General Meeting brings together the alliance of vaccine manufacturers from developing countries, producers whose capacity determines how fast a region can respond to its own outbreaks, rather than depending on supply decided elsewhere. Jose Castillo, our CEO, and Maria Davila-Saignol, our Director Global South & Asia Pacific, will be there from 22 to 24 September. If building RNA manufacturing capability is on your roadmap, come and talk to
- RNA discovery is moving faster than RNA translation. Closing that gap is the interesting problem. The 3rd RNA Horizons Conference takes it head on. Three days in Munich spanning mis-splicing in human disease, epitranscriptomic regulation, non-coding RNAs as drug targets, AI in RNA medicine; and then the harder question the field can't avoid: what it actually takes to turn any of it into a viable therapy. Delivery technologies. Manufacturing. Commercialisation and market access. That last stretch is where we work. Dr. Ashiqul Haque,
- An RNA therapeutic doesn't begin at the bioreactor. It begins at the sequence. That's where the 4th RNA Vaccines and Therapeutics Conference starts too. Session 1 is devoted entirely to RNA design and optimisation. And we're glad to be part of it! Youlia Serikova, our Head of N-Force Process, will present "From RNA Technology to Medicines: Enabling Scalable, Accessible mRNA-based Medicines Manufacturing" on Tuesday 15 September, Day 1, Session 1. She'll be joined across both days by Guillaume Roelandts, our Director of
- PRESS RELEASE: We are proud to share a major milestone in mRNA vaccine manufacturing and epidemic preparedness! Quantoom Biosciences Ntensify® technology for RNA production and purification is being used for Brazil's first mRNA vaccine, developed on Fiocruz own mRNA platform, which has just received authorization from Anvisa (Brazilian Health Regulatory Agency) to begin clinical trials. This milestone highlights the power of combining: 🔹 Fiocruz's leadership as the first WHO Global mRNA Technology Transfer Programme partner
- RNA World 2026 makes a claim we agree with: RNA is no longer just a modality. It's becoming infrastructure. The organisers frame RNA medicine as three interdependent layers: CODE (what to build), ENGINE (making it work), CURE (making it real). It's a useful lens, because most programmes don't stall on the science. They stall between the layers: an elegant sequence that has no delivery route, or a process that works beautifully until scale changes the rules. That gap is where we work. Wen Hong Toh, our Senior Business Developer
- We're excited to be part of this program! #WorldUpstart #Lifesciences #MedTech #HealthcareInnovation #Philadelphia
- CAR-T is moving in vivo. And that changes what sits on the critical path. This week in Lille, the 10th International Symposium on CAR T Cells dedicates a full session to in vivo cell reprogramming, alongside a keynote on in vivo T-cell therapy, talks on allogeneic CAR-T, and AI-guided receptor design. RNA runs through all of them. DIDIER ARGENTIN, our Senior Sales Director Europe, will be at the Faculté de Médecine, Pôle Recherche on 10–11 September to talk RNA — and our N-Force toolbox, from sequence design to delivery. If
- We're pleased to share that Maria Davila-Saignol, Director Global South & Asia Pacific at Quantoom Biosciences, will be taking part in the UKSEA Vax Hub Workshop, hosted as part of the Sarawak Infectious Disease Centre (SIDC) Shine Conference. 📍 Sarawak, Malaysia | September 9–11 The workshop brings together partners from the UK and Southeast Asia working to strengthen regional vaccine research, development and manufacturing capabilities. If you're attending, reach out to Maria — she'd be glad to connect and explore how we can
Something wrong or missing? Send an update. Fixed within 24 hours.